Skip to main content
Edmund Waller, MD, Oncology, Atlanta, GA

EdmundKWallerMD

Oncology Atlanta, GA

Hematologic Oncology

Professor of Hematology & Oncology, Emory University

Dr. Waller is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Waller's full profile

Already have an account?

  • Office

    1365 Clifton Rd NE
    Atlanta, GA 30322
    Phone+1 404-727-4995

Summary

  • Dr. Edmund Waller is a hematologist oncologist in Atlanta, GA and is affiliated with multiple hospitals in the area, including Emory University Hospital, Emory University Hospital Midtown, and Grady Memorial Hospital. He received his medical degree from Weill Cornell Medical College of Cornell University and his PhD from Rockefeller University. Following clinical training in Medicine and Medical Oncology at Stanford University and working at Becton Dickinson in San Jose, he has been in practice at Emory for 27 years. He manages an active R01 and P01-funded basic science and translational research laboratory. He has founded two biotech start-ups, Cambium Medical Technologies, a clinical stage company developing Elate Ocular to treat ocular GvHD, and Cambium Oncology, a pre-clinical company developing first-in-class antagonists of a novel immune check-point pathway mediated by signaling through the receptor for vasoactive intestinal polypeptide (VIP). He has clinical expertise in hematologic oncology, cancer immunotherapy, CART, and hematopoietic stem cell transplantation for lymphoma, myeloid malignancies, sickle cell anemia and germ cell cancer. .

Education & Training

  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1988 - 1993
  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1985 - 1988
  • Weill Cornell Medicine
    Weill Cornell MedicineClass of 1985
  • Rockefeller University
    Rockefeller UniversityPhD, Chemical Biology, 1978 - 1984
  • Harvard University
    Harvard UniversityAB, Biology, Magna Cum Laude, 1974 - 1978

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1987 - Present
  • GA State Medical License
    GA State Medical License 1995 - 2025
  • TX State Medical License
    TX State Medical License 1993 - 1995
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2011-2022
  • America's Top Doctors for Cancer Castle Connolly, 2011-2022

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • The Potential of CAR T Cell Therapy in Pancreatic Cancer  
    Mehmet Akce, Mohammad Y Zaidi, Edmund K Waller, Frontiers in Neurology
  • Recipient Single Nucleotide Polymorphisms in Paneth Cell Antimicrobial Peptide Genes and Acute Graft‐Versus‐Host Disease: Analysis of BMT CTN‐0201 and ‐0901 Samples  
    Armin Rashidi, Edmund K Waller, Bharat Thyagarajan, Claudio Anasetti, Daniel J Weisdorf, Bart L Scott, Bruce R Blazar, British Journal of Haematology
  • Indoles Derived from Intestinal Microbiota Act via Type I Interferon Signaling to Limit Graft-Versus-Host-Disease  
    Edmund K Waller, Zachariah DeFilipp, Muna Qayed, Akshay Sharma, Blood

Abstracts/Posters

  • Outcomes of Elderly Patients Undergoing Allogeneic Transplantation for Acute Myeloid Leukemia with Fludarabine/Melphalan or Fludarabine/TBI Conditioning Regimen
    Edmund K. Waller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizu...
    Edmund K. Waller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • IMPACT-TB*: A Phase II Trial Assessing the Capacity of Low Dose Imatinib to Induce Myelopoiesis and Enhance Host Anti-Microbial Immunity Against Tuberculosis. *Imatini...
    Edmund K. Waller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial o... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

  • Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic MalignanciesDecember 2023

Press Mentions

  • Research Roundup: Recent Grants and Publications for Emory Faculty and Staff
    Research Roundup: Recent Grants and Publications for Emory Faculty and StaffMarch 10th, 2022
  • Research Roundup: Recent Grants and Publications for Emory Faculty and Staff
    Research Roundup: Recent Grants and Publications for Emory Faculty and StaffSeptember 21st, 2021
  • NIAID Supports Clinical Testing of Anti-Cancer Drug for TB
    NIAID Supports Clinical Testing of Anti-Cancer Drug for TBAugust 15th, 2017
  • Join now to see all

Grant Support

  • Using donor dendritic cells to optimize GvHD and GvL in allogeneic stem cell transplantationNIH/NCI/NHLBI2020–2025
  • Development of Gleevec for TB and TB/HIVNIH/NIAID2015–2022
  • Modified Donor Lymphocytes Infusion (MDLI) For Rapid Immune ReconstitutionNational Heart, Lung, And Blood Institute2011
  • Immunologic And Virologic Monitoring Laboratory CoreNational Heart, Lung, And Blood Institute2011
  • Clinical Trials- Shared ResourcesNational Cancer Institute2009–2011
  • Separating Antitumor &Gvhd In Allogeneic T-CellsNational Cancer Institute2003–2007
  • Adoptive Transfer Of Immunity In Bone Marrow TransplantationNational Center For Research Resources1999–2002
  • Antileukemic Effect Of Irradiated Allogeneic LymphocytesNational Cancer Institute1998–2000

Committees

  • Member, NCI Leukemia Committee 2018 - Present

Professional Memberships